S

Sanofi

Global pharma company; vaccines and R&D

Global Therapeutic Area Head - Rhinology & Gastroenterology

Full-TimeDeadline 12/18/26
$293.3k - $423.6k
Expert
Bachelor's, MBA
Cambridge, MA, USA
Hybrid
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • 15+ years of progressive experience in biopharmaceutical commercialization, with a track record of delivering results in complex, matrixed, global environments.
  • Demonstrated global and local marketing leadership experience, preferably including U.S. commercial experience, with experience in marketing strategy, launches, brand planning, omnichannel, forecasting, budgeting, and resource allocation.
  • Experience collaborating cross-functionally with R&D, Medical Affairs, Market Access, and Public Affairs, including biologics launch experience and the ability to drive market-shaping activities and evidence generation.
  • Experience advancing customer and patient engagement at country and global levels.
  • Strong differentiator: experience in respiratory, rhinology, gastroenterology, or related specialty/immunology therapeutic areas.
  • Significant advantage: alliance management experience and exposure to executive committee governance.
  • Demonstrated experience leading and inspiring teams and attracting, developing, and retaining talent.
  • Strong P&L management experience, including global revenue forecasting, budget ownership, and ROI-driven investment decision-making.
  • Ability to lead through influence, inspire teams, leverage strengths, and provide meaningful feedback, coaching, and support.
  • Ability to operate effectively across diverse cultural environments and manage stakeholders effectively.
  • Bachelor's degree required, preferably in life sciences, marketing, or business.
  • Fluent in English.
Responsibilities
  • Develop and own the global brand strategy, positioning, and go-to-market plan for the Rhinology & Gastroenterology portfolio across CRSwNP, AFRS, and EoE, aligning with company vision, alliance commitments, and market opportunities.
  • Co-create short-, mid-, and long-term strategic ambitions with key markets, alliance partners, and external stakeholders, translating insights into a differentiated value proposition.
  • Facilitate strategy reviews, alignment forums, and knowledge-sharing sessions with local markets to drive global-to-local coherence and improve in-market performance.
  • Develop global campaigns, best-practice playbooks, and modular content for local market execution.
  • Drive market-relevant initiatives to address barriers to biologic adoption in CRSwNP and EoE, including referral pathway gaps, diagnostic delays, and low disease awareness.
  • Build awareness and engagement among ENT specialists, allergists, and gastroenterologists to accelerate appropriate patient identification.
  • Drive differentiation and market leadership across CRSwNP, AFRS, and EoE with a distinct, enduring value proposition versus competitors.
  • Attract, develop, and retain talent and lead a high-performing cross-functional team.
  • Serve on the Global Immunology Alliance Leadership Team and contribute to franchise-level initiatives through best-practice sharing, mentoring, and enterprise leadership.
  • Create and communicate an organizational vision that engages teams across functions, geographies, and levels.
  • Own full P&L accountability for the global Rhino-Gastro franchise and lead strategic and financial planning across indications.
  • Own and update global revenue forecasts across markets, grounding projections in analysis and strategic priorities.
  • Own and manage the global commercial operating budget, allocating investments based on ROI and managing resources with discipline.
  • Develop and track KPIs to assess global and local/regional commercial activities and hold the franchise accountable to performance standards.
  • Collaborate with R&D, Medical Affairs, Clinical Program Management, and alliance partners to develop a lifecycle strategy aligned with the franchise vision.
  • Represent the global commercial perspective in lifecycle-management governance and R&D clinical development programs, incorporating commercial viability and patient relevance into development decisions.
  • Lead commercial strategy development, conduct commercial assessments, and support business cases for pipeline and lifecycle opportunities across CRSwNP, AFRS, and EoE.
  • Identify development opportunities, including new indications, patient segments, and combination approaches, to maximize long-term portfolio value.
  • Represent the franchise's commercial interests in alliance governance and executive committee discussions.
Desired Qualifications
  • An MBA or other advanced degree is strongly preferred.
  • Experience in respiratory, rhinology, gastroenterology, or related specialty/immunology therapeutic areas is a strong differentiator.
  • Alliance management experience and exposure to executive committee governance are significant advantages.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...